Introduction

Low back pain is an important priority for our healthcare system. Symptomatic low back pain affects nearly three in four people over a lifetime, and approximately one third of adults in the past 3 months in the United States [1, 2]. Pain can originate from numerous overlapping osseous and soft tissue structures of the spine and surrounding tissues, resulting in up to 85% of cases lacking a precise pathoanatomic diagnosis [3], termed nonspecific low back pain. More serious underlying pathologies causing low back pain are identified by “red flag” features (weight loss, fevers, night pain, etc.) and are much less common than nonspecific low back pain [4], with a 4% incidence of compression fracture, 0.7% incidence of neoplasm, and a 0.01% incidence of infection [3]. Given the prevalence of nonspecific low back pain and the low rate of acute pathology, routine imaging of low back pain without “red flag” features is not recommended [3, 5]. However, approximately one quarter of patients presenting to primary care clinics and one half of patients presenting to the emergency department with a chief complaint of low back pain receive imaging studies [6]. Therapeutic interventions for patients with low back pain have increased steadily over the past decades. Percutaneous injections for patients with persistent symptoms and spondylotic changes on imaging are becoming increasingly common; facet joint interventions in Medicare patients increased 386% between 2000 and 2011 and remain more common than in prior decades, despite a slight decrease in recent years [7]. Surgery for low back pain has more than doubled during the same period with an increase in the invasiveness of surgical interventions [8]. Imaging to prove accuracy of identifying a pain generator for nonspecific low back pain would be valuable in guiding an evidence-based approach to non-operative and operative interventions.

Lumbar spine radiographs offer moderate sensitivity and varying specificity for neoplastic (sensitivity 60%, specificity 95–99.5%) and infectious (sensitivity 82%, specificity 57%) etiologies of back pain [9], but findings of degenerative changes on radiographs have, at best, a weak correlation with the clinical symptoms of low back pain [10, 11]. Cross-sectional anatomic imaging modalities have improved sensitivity and specificity for spondylotic changes associated with back pain [9, 12,13,14,15]. However, the high prevalence of these changes in asymptomatic patients [16,17,18,19] highlights the “specificity challenge.” Advanced imaging is most useful when it identifies a specific pathology that leads to a precise and focused approach to care. Many studies have demonstrated only a limited association between findings on CT and/or MRI and the presence/severity of low back pain [18,19,20,21,22,23∙]. Furthermore, there is no clear correlation between spondylotic changes on CT/MRI (specifically, facet arthropathy and spinal canal stenosis) and a clinical response to subsequent percutaneous steroid injections [24,25,26]. Similarly, surgery for low back pain has been unreliable, and imaging has had limited utility in guiding surgery for nonspecific low back pain [27, 28].

Molecular imaging with bone-targeted agents such as Tc-99m methylene diphosphonate (MDP) and 18F-sodium fluoride (NaF) can identify areas of active bone remodeling through selectively increased radiotracer uptake in osteoblastic activity and synovial hyperemia [29, 30]. When used in conjunction with anatomic imaging, molecular imaging with single-photon emission-computed tomography (SPECT) or positron emission tomography (PET) shows promise to more accurately identify active pain generators [31,32,33]. Several retrospective and prospective studies evaluating the ability of SPECT and SPECT/CT to identify pain generators and predict response to treatment have demonstrated promising results. However, there still remains some controversy regarding the specificity of molecular imaging to identify a source of back pain [29, 33,34,35,36,37,38,39]. Additional molecular imaging modalities such as PET/CT and PET/MRI using NaF and fluorodeoxyglucose (FDG) radiotracers have been reported in the literature, and the preliminary studies have shown similarly favorable results [40,41,42,43]. In this article, we present a review of the current literature regarding the imaging of back pain to guide management, with a focus on molecular imaging (Fig. 1).

Fig. 1
figure 1

Facet arthropathy (arrowhead) demonstrated on radiograph (a), computed tomography (b), magnetic resonance imaging (c), and MDP SPECT/CT (d)

Full size image

Workup and Management of Low Back Pain

Current Anatomic Imaging Modalities

Precise evaluation of sensitivity and specificity for disk and facet pathology on lumbar spine-imaging studies is somewhat limited given the lack of a universally accepted gold standard test for identifying the source of lower back pain [20]. Within this limitation, the diagnostic accuracies of commonly used imaging modalities are discussed below.

Radiography is mainly useful for identifying severe underlying osseous pathology. Plain films of the lumbar spine have demonstrated 60% sensitivity and 95–99% specificity for malignancy, 82% sensitivity, and 57% specificity for infection, and 26–45% sensitivity and 100% specificity of ankylosing spondylitis [9]. Plain films are also useful and accurate for identification of spinal deformity including scoliosis, spondylolisthesis, and rotatory subluxation. For nonspecific low back pain, there are no clinically validated sensitivity and specificity values of lumbar spine radiographs reported in the literature. Furthermore, up to 75% of lumbar spine radiographs yield no information regarding a precise cause of low back pain [44]. Two systematic reviews have shown an association between low back pain and degenerative changes on radiographs characterized by disk space narrowing [10, 11], endplate sclerosis, and osteophytosis, with the odds ratios for these associations ranging from 1.2 to 3.3 [11]. However, several of the included studies were identified as having potential significant biases leading to an overestimation of association [11]. No association has been demonstrated between low back pain and spondylolisthesis, spondylolysis, transitional vertebrae, Scheuermann’s disease [11], and facet disease [10] on radiographs.

Computed tomography of the lumbar spine has improved sensitivity and specificity compared to plain radiography. CT has been reported to have 86.7% sensitivity and 78.6% specificity for facet disease [15]; 62–90% sensitivity and 70–87% specificity for herniated intervertebral disk [9]; and 90% sensitivity and 80–96% specificity for spinal canal stenosis [9]. Despite the relatively high sensitivity and specificity for these degenerative processes, a cross-sectional study by Kalichman et al. demonstrated no statistically significant association between these findings on CT and self-reported low back pain. The only feature strongly associated with low back pain was spinal stenosis, and this relationship did not reach statistical significance (OR 2.87 [95% CI 0.93–8.87]) [45].

Magnetic resonance imaging of the lumbar spine is typically considered to be the gold standard for anatomic imaging of the spine. With superior soft tissue resolution compared to CT, MRI is able to distinguish different structures within the intervertebral disk, visualize ligaments, assess bone marrow composition, and evaluate the contents of the spinal canal [9]. MRI has a reported 87–93% sensitivity and 64.3–87% specificity for facet disease [13, 15]. However, one study demonstrated a decreased sensitivity of 40–53% when attempting to precisely localize the painful facet [13], suggesting a poor or incomplete correlation between facet arthropathy and active pain generators. For evaluation of herniated disk, the MRI literature varies widely, reporting a range of 60–100% sensitivity and 43–97% specificity [9]. However, a systematic review of 8 studies demonstrated 75% sensitivity and 77% specificity of MRI for herniated disk on a pooled analysis. The diagnostic accuracy for associated nerve root compression was evaluated in two of the included studies which demonstrated high sensitivity of 81 and 92% and variable specificity of 52 and 100% [14]. MRI has 77–96% sensitivity and 68–100% specificity for lumbar spinal stenosis [12, 14].

While CT and MRI have good sensitivity and specificity for symptomatic nerve compression or facet arthropathy, the utility of CT and MRI in identifying a pain generator in nonspecific low back pain is limited [4]. Many spondylotic changes, so called “degenerative findings,” seen on lumbar spine CT and MRI are also highly prevalent in asymptomatic patients, indicating that they may represent normal age-related changes [17, 45]. For example, Boden et al. demonstrated that within a cohort of asymptomatic patients older than 60, 36% had a herniated disk, 21% had spinal stenosis, and more than 90% had disk degeneration on MRI [16]. Similar prevalence was demonstrated on CT in a nonselected group of patients older than 60; 87.5% had facet arthropathy, 16.3% had spinal stenosis, 35.4% had degenerative spondylolisthesis, and 83.3% had disk space narrowing [45]. Given the high frequency of degenerative lumbar spine findings in asymptomatic individuals, using a specific anatomic finding to definitively diagnose the cause of low back pain is of limited value [18, 19].

A meta-analysis evaluating the ability of MRI findings to identify the facet joints, intervertebral disk, and/or sacroiliac joint as the cause of lower back pain determined that no MRI features could significantly predict facet or sacroiliac sources of pain. Furthermore, the absence of disk degeneration could only moderately rule out a discogenic pain source [20]. Additional studies comparing MRI findings with Oswestry Disability Index demonstrated only a weak correlation of symptoms with disk degeneration and specifically right L5–S1 facet disease, and concluded that imaging alone is insufficient to explaining sources of low back pain [21, 22].

Multiple longitudinal studies following asymptomatic patients demonstrated limited associations between the development of new MRI findings and incident axial low back pain [18, 19, 23∙], with one study finding a stronger association with depression than with new imaging findings [18]. New annular fissures were the only MRI finding that demonstrated a statistically significant association with incident axial low back pain in one study (OR 6.0 [95% CI 1.1–33.1]). However, symptoms only developed in half of the cases [19] and this relationship was not seen in other studies [18, 23∙]. Additionally, in Javrik, et al., the only statistically significant association with MRI findings was the presence of a disk protrusion as a negative predictor for future back pain (HR 0.5 [95% CI 0.3–0.9)]. Disk extrusion, nerve root contact, and central canal stenosis were associated with incident low back pain (HRs ranging from 1.2 to 2.2) but were not statistically significant [18]. While no strong correlation between MRI findings and low back pain was demonstrated in these longitudinal studies, they were all limited by small sample size and low incidence of new MRI findings. Conversely, a meta-analysis by Brinjikji et al. demonstrated that in adults 50 years of age and younger, certain MRI findings were more prevalent in symptomatic compared to asymptomatic individuals—disk bulge (OR 7.54; 95% CI 1.28–44.56; P = 0.03), spondylolysis (OR 5.06; 95% CI 1.65–15.53; P < 0.01), disk extrusion (OR 4.38; 95% CI 1.98–9.68; P < 0.01), Modic 1 changes (OR 4.01; 95% CI 1.10–14.55; P = 0.04), disk protrusion (OR 2.65; 95% CI 1.52–4.62; P < 0.01), and disk degeneration (OR 2.24; 95% CI 1.21–4.15; P = 0.01). Of note, several of these findings (disk bulge, disk protrusion, and disk degeneration) demonstrated I2 values > 62% suggesting substantial heterogeneity in reported results [46]. This suggests that some anatomic findings may have an association with back pain in a younger adult population, perhaps prior to development of more ubiquitous degenerative changes in later decades of life. The review of the literature highlights the limitation of anatomic imaging in addressing the “specificity challenge” of identifying a specific pain generator on a background of asymptomatic or noncontributory spondylotic changes, especially in the older adult population.

Several studies have shown no significant correlation between the pathoanatomic findings of facet arthropathy on MRI and CT with the clinical response to targeted facet joint infiltration [24,25,26] or rhizotomy [47]. Despite the poor ability of pathoanatomic findings on CT and MRI to predict if a particular facet is a pain generator, recent systematic reviews have shown fair evidence for therapeutic infiltrations [48]. Likewise, facet joint denervation with radiofrequency ablation (RFA) has demonstrated a pain relief success rate of 55–68% at 1 year [49]. Of note, use of posttreatment pain relief as a diagnostic gold standard is limited due to a high false-positive rate of a single injection, up to 38% for intra-articular injections [50] and 45% for single medial branch blocks [51]. The false-positive rate was determined by comparing the response rate of an initial lidocaine injection to a subsequent confirmatory bupivacaine injection in the same location. In both studies, a significant number of patients did not demonstrate reproducible symptomatic improvement on confirmatory injection—26 of the 83 patients for intra-articular injection [50] and 83 of the 150 patients for medial branch block [51]. This high rate may be secondary to leakage of injectate into periarticular structures [24] and anesthesia of the muscles, ligaments, and periosteum also innervated by the medial branch nerve [25∙], respectively.

Diphosphonate SPECT/CT

Disphosphonate SPECT/CT can be performed for molecular imaging of back pain. Methyldiphosphonate (MDP) and hydroxydiphosphonate (HDP) are phosphate analogues which complex with the hydroxyapatite mineral phase of bone, a process known as chemisorption. These compounds can be labeled with Tc-99m for single-photon emission-computed tomography (SPECT) imaging to identify areas of active bone remodeling, characterized by increased osteoblastic activity and synovial hyperemia [29, 30]. This environment is seen in facet joints undergoing osteoarthritic changes [29]. The degree of uptake can differentiate an actively growing osteophyte from stable, mature osseous growth which could account for differences in response to therapy, with sites of active remodeling responding better than mature changes [39]. SPECT can be fused with CT which, in theory, combines the high sensitivity of SPECT with the anatomic specificity of CT, allowing for superior spatial resolution and more accurate localization of the diseased structure [31,32,33]. A retrospective study by Matar et al. found that SPECT/CT could identify potential pain generators in 92% of cervical spine scans and 86% of lumbar spine scans with precise localization of target facet joints in 65% of patients [32]. When used in conjunction with cross-sectional imaging, SPECT provides additional specificity for facet joint arthropathy by differentiating the frequent incidental, asymptomatic findings from the significant ones [31]. Additionally, SPECT/CT has been shown to have high diagnostic accuracy in the evaluation of sacroiliac joint dysfunction with reported sensitivity 95% of and specificity of 99% [52] as well as for the identification of hardware loosening in postoperative patients with recurrent back pain (sensitivity 100%, specificity 89.7%) [53].

In the literature, the diagnostic accuracy of SPECT and SPECT/CT is limited and differs if intra-articular facet injection or medial branch block is used as the comparative gold standard. Compared with responses to facet injections, the sensitivity and specificity of SPECT for facet disease are 79–100% and 70–71%, respectively [34, 35, 54]. Compared to medial branch block, the sensitivity and specificity of SPECT are 96–100% and 45–50%, respectively [37]. In contrast, the one study determining the accuracy of SPECT/CT compared with medial branch block demonstrated at sensitivity of 57% and a specificity of 77% [36].

There have been multiple studies showing favorable results regarding the use of SPECT and SPECT/CT to identify pain generators that are likely to respond to injection. An early prospective study in 1996 by Dolan et al. compared the outcome of 58 patients who underwent SPECT and then received facet injections directed by SPECT findings if the scan was positive and clinical exam if the scan was negative. The positive SPECT group demonstrated significant improvement in VAS (visual analog scale) and McGill pain scores compared to the SPECT negative group; of those with positive scans, 95% reported symptomatic improvement at 1 month compared to 47% in the negative scan group [35]. In a randomized control trial by Pneumaticos et al. in 2006, patients with back pain received facet joint injections either guided by SPECT findings or clinical exam findings (n = 47). For the SPECT group, 87% of patients treated at the site of increased tracer uptake had significant symptom relief compared with 13% of those with a negative SPECT and 31% of the control group. Additionally, the number of therapeutic injections was decreased from 60 to 27 in patients with positive scans [39]. A prospective study by McDonald et al. in 2007 performed SPECT/CT on 37 patients with clinically diagnosed facetogenic back pain who then underwent facet joint injection and/or rhizotomy targeted to specific facet joints identified on SPECT-CT. 36 of the 37 patients experienced symptomatic improvement with a mean improvement of 4.4 ± 1.6 VAS (visual analog scale) points [33]. A similar prospective study by Koh et al. in 2011 obtained SPECT on 33 patients with suspected facetogenic chronic low back pain and performed a medial branch block based on imaging (for SPECT-positive patients) or clinical exam (for SPECT negative patients). 85.7% of the SPECT-positive patients were responders at 2 weeks versus 20% of the SPECT negative patients; at 2 weeks, the VAS score of the SPECT-positive group was 3.13 ± 1.54 and 5 ± 2.28 for the SPECT negative group, decreased from 6.8 ± 1.8 and 6.33 ± 1.87, respectively [37]. An additional randomized control trial by Jain in 2015 (n = 80) compared pain relief after nerve block between patients receiving a pre-procedural SPECT/CT and a control group using only clinical features and radiologic findings to arrive at a clinical diagnosis. The number of patients reporting significant pain relief was higher in the SPECT/CT group with 80% obtaining > 50% improvement and 70% obtaining 70–100% improvement. In contrast, the control group demonstrated 52.5% obtaining > 50% improvement and 25% obtaining 70% improvement [55]. A retrospective study by Lee et al. in 2014 reviewed 175 patients who had undergone SPECT/CT for chronic low back pain. Of the patients that underwent target specific treatment, an 82.6% response rate was seen for those with definite focal uptake on SPECT versus a 54.8% response rate for the patients with no or mild uptake [29]. A more recent case series in 2019 by Kato et al. reviewed 5 patients with low back pain initially diagnosed with adult spinal deformity based on clinical exam and anatomic imaging. All 5 patients had planned extensive spinal fusion, however pre-operative SPECT/CT demonstrated more localized degenerative pain generators and even isolated endplate and transverse process fractures. Based on these findings, 3 patients underwent minor segmental fusion and 2 patients were treated conservatively; all patients achieved significant reduction in pain based on an 11-point pain scale, from 8.4 ± 0.5 to 2.2 ± 1.3 [56∙∙].

Conversely, a study by Lehman et al. in 2014 demonstrated a discrepancy between SPECT/CT findings and treatment. In this retrospective study of 74 patients, only 47% of the treated facets were positive on SPECT/CT, and only 70% of facets with increased uptake were selected for treatment, suggesting that findings do not always translate into changes of clinical practice [38]. Additionally, Freirmuth et al. performed a randomized control trial in which 29 patients underwent medial branch blocks based on clinical exam followed by the unblinding of the proceduralist to the SPECT/CT with additional blocks performed at untreated levels if the initial infiltrations were negative. In contrast to the previously discussed studies, there was only a modestly increased response rate, from 17 to 24%, with SPECT/CT. The sensitivity and specificity were found to be 0.57 and 0.77 [36].

Of note, a study by Ackerman et al. demonstrated that there was a significantly greater improvement in pain and disability scores with intra-articular injections compared with medial branch blocks in patients with SPECT-positive facets [34]. This difference may account for some of the variability seen in the above studies.

There have been multiple cases at our institution where findings on MDP SPECT/CT have been used to guide clinical management, including surgical interventions. Several such cases are presented which highlight the use of molecular imaging in identifying facet arthropathy (Fig. 2), degenerative disk disease (Fig. 3), sacroiliitis (Fig. 4), adjacent segment disease (Fig. 5), and pseudoarthrosis (Fig. 6). The impact of molecular imaging on clinical outcomes remains to be demonstrated.

Fig. 2
figure 2

Facet arthropathy. A 54-year-old woman with chronic back pain had an MRI lumbar spine (a) at an outside facility which revealed multilevel degenerative disk disease (white arrowhead) and facet arthropathy (white arrow) without a definite level of most severe disease. Based on the nonspecific MRI findings and clinical evaluation, she underwent an epidural spinal injection which provided no improvement in symptoms. After referral to our spine center, a SPECT/CT (b) was performed which demonstrated focal increased uptake in the left L4–L5 and L5–S1 facet joints (yellow arrow), suggesting a facetogenic source of pain. Subsequent bilateral facet injections at these levels provided symptomatic relief (Color figure online)

Full size image
Fig. 3
figure 3

Degenerative disk disease. A 84-year-old woman with chronic neck pain after a remote injury while white-water rafting underwent MRI cervical spine (a) which showed severe multilevel degenerative disk disease worst at C4–C5 and C6–C7 as well as facet arthropathy worst on the right C3–C4 and C7–T1 (white arrowhead). Given the degree of facet arthropathy and clinical presentation, the patient was referred for facet joint injection. Over the course of three visits, the patient had numerous CT-guided facet injections (b, c) of the bilateral C2–C3, right C3–C4 and C4–C5, bilateral C5–C6, C6–C7, and C7–T1 facet joints (white arrows at right C3–C4 and right C7–T1) with suboptimal symptomatic relief. After the third procedure, an SPECT/CT was obtained (d) which revealed intense focal uptake centered in the C4–C5 disk space (yellow arrowhead), consistent with a discogenic rather than facetogenic pain generator. These findings prompted a CT-guided epidural steroid injection (e) at C6–C7 (yellow arrow) which resulted in marked improvement of pain  (Color figure online)

Full size image
Fig. 4
figure 4

Sacroiliitis. A 74-year-old man status post complex spine reconstruction resulting in fusion from C5–S1 fusion and a right sacroiliac bolt presented with new low back pain radiating into the left hip. Radiography demonstrates extensive fusion of the cervical spine through pelvis without evidence of hardware complication or pseudoarthrosis (a). On subsequent SPECT/CT (b), there is isolated increased uptake in the left sacroiliac joint (white arrows) without associated morphologic changes, likely secondary to altered biomechanics following fusion. In the context of the SPECT/CT findings, the patient was taken back to the OR for revision of the spinal hardware with new fusion across the left sacroiliac joint (c). Patient reported improvement in pain following revision

Full size image
Fig. 5
figure 5

Adjacent segment disease. A 67-year-old woman presenting with low back pain and right leg pain with a history of L4–L5 total disk replacement for recurrent disk herniations > 15 years prior. An initial CT (a) identified the L4–L5 disk replacement (white arrows), bilateral facet arthropathy at L4–L5 (yellow arrows), and degenerative disk disease at L2–L3 and L3–L4 (black arrows). Given the clinical findings, her back pain was attributed to the facet arthropathy. However, a SPECT/CT obtained prior to intervention (b) demonstrated markedly increased uptake within the L3–L4 disk space (white arrowhead), most consistent with adjacent segment disease. The facet joints and L4–L5 disk space did not have significant uptake to suggest facetogenic pain generators or hardware complication. The patient subsequently underwent posterior spinal fusion spanning L2–L5 with significant symptomatic improvement (Color figure online)

Full size image
Fig. 6
figure 6

Pseudoarthrosis. A 62-year-old man with 7 years of low back pain for which he had a microdiscectomy and ALIF at L5–S1 which provided only partial symptom relief. An outside CT (a) revealed facet arthropathy of the bilateral L5–S1 facet joints (white arrows) and no evidence of hardware failure. His pain was felt to be facetogenic in nature and bilateral L5–S1 facet injections were performed with transient resolution of pain. A subsequent SPECT/CT was obtained, (b) which demonstrated intense uptake at the level of the L5–S1 fusion (yellow arrows), compatible with pseudoarthrosis. Based on these findings, the patient underwent L5–S1 posterior spinal fusion and decompression with excellent postoperative pain relief (Color figure online)

Full size image

18F-FDG and 18F-NaF PET/CT and PET/MRI

Like SPECT/CT, PET can be combined with CT or MRI to provide superimposed metabolic and anatomic information. Due to the higher intrinsic spatial resolution of PET compared to planar and SPECT imaging, PET/CT or PET/MRI may identify pathologies more accurately with shorter imaging times [57]. Several smaller studies have investigated the use of 18F-NaF and 18F-fluorodeoxyglucose (18F-FDG) radiotracers in the evaluation of back pain.

NaF localizes to the hydroxyapatite matrix of bone in areas of osseous remodeling via hydroxyl ion exchange, similar to MDP, though with significantly less binding to serum proteins, allowing for earlier image acquisition [41, 57]. Several early studies have shown promising results of NaF PET/CT and PET/MRI in identifying potential spinal pain, with a sensitivity as high as 88% [43]. A retrospective study by Mabray et al. demonstrated a weak positive correlation between degree of NaF uptake and Pathria CT morphologic grade of facet arthropathy. There was a wide range of SUVs within each Pathria grade, and some Pathria grade 0 (normal) facets demonstrated uptake while some grade 4 (advanced disease) facets demonstrated minimal to no uptake; these findings suggest a discrepancy between molecular and anatomic imaging with possible metabolic changes preceding morphologic changes [41]. Similarly, a prospective study evaluating low back pain patients with NaF PET/MRI showed a strong correlation between a kinetic measure of dynamic NaF uptake (Ki_Patlak) and Oswestry disability index scores, but only a weak correlation with MRI arthropathy grade [42∙]. An additional case series performed by Pouldar et al. focused on NaF PET/CT performed in patients with persistent back pain following surgery. In 18 of the 25 cases, the results of the PET/CT changed the diagnosis and/or management, including 6 cases of pseudoarthrosis and 5 cases of hardware impingement or loosening that were not seen on CT or MRI [58]. While these studies show encouraging results, they are significantly limited by small sample sizes and the lack of confirmatory anesthetic joint injections or nerve blocks.

In contrast, FDG localizes to areas of increased glucose utilization, and its use in bones has traditionally been to identify metastatic lesions and infection. However, the FDG accumulation can also be seen within foci of inflammation such as active degenerative changes [59]. A retrospective study on 150 patients undergoing FDG PET/CT for evaluation of any known or suspected malignancy demonstrated a weak but statistically significant correlation between the degree of degenerative disk and facet changes and FDG avidity, with substantial variability in the intensity of FDG uptake in areas of severe degenerative change [59]. Like the similar studies done with NaF PET, this may represent the degree of active bone remodeling at the time of imaging superimposed on the more chronic morphological changes that develop over years. Sawicki et al. performed a prospective trial in which 10 patients underwent FDG PET/MRI of the cervical spine followed by facet injection targeted to focal FDG uptake, if present, versus clinical localization and level of maximum morphological arthrosis. The 6 PET-positive patients had significantly reduced posttreatment pain levels (7.5 ± 1.0 pretreatment to 2.3 ± 1.0 at 3 h), while the 4 PET-negative patients demonstrated no significant pain reduction (6.75 ± 2.1 pretreatment to 6.0 ± 1.8 at 3 h) [40]. This study’s outcomes mirror the findings seen in several of the prospective trials on MDP SPECT/CT-targeted injections, although they are limited by the small number of patients.

Conclusion

Molecular imaging, including SPECT/CT, PET/CT, and PET/MRI, have demonstrated improved diagnostic accuracy in identifying active pain generators compared to anatomic imaging alone. MDP SPECT/CT has been the most studied molecular imaging modality with a majority of the literature supporting its improved sensitivity and specificity. PET/CT and PET/MRI using NaF, and to a lesser extent FDG, demonstrate promising preliminary data; however, additional large prospective randomized trials are needed to confirm these results. If supported, these PET modalities have even greater utilization potential given the higher intrinsic spatial resolution and shorter imaging times compared to SPECT.